title: The effect of anandamide on uterine nitric oxide synthase activity depends on the presence of the blastocyst.
abstract: Nitric oxide production, catalyzed by nitric oxide synthase (NOS), should be strictly regulated to allow embryo implantation. Thus, our first aim was to study NOS activity during peri-implantation in the rat uterus. Day 6 inter-implantation sites showed lower NOS activity (0.19±0.01 pmoles L-citrulline mg prot(-1) h(-1)) compared to days 4 (0.34±0.03) and 5 (0.35±0.02) of pregnancy and to day 6 implantation sites (0.33±0.01). This regulation was not observed in pseudopregnancy. Both dormant and active blastocysts maintained NOS activity at similar levels. Anandamide (AEA), an endocannabinoid, binds to cannabinoid receptors type 1 (CB1) and type 2 (CB2), and high concentrations are toxic for implantation and embryo development. Previously, we observed that AEA synthesis presents an inverted pattern compared to NOS activity described here. We adopted a pharmacological approach using AEA, URB-597 (a selective inhibitor of fatty acid amide hydrolase, the enzyme that degrades AEA) and receptor selective antagonists to investigate the effect of AEA on uterine NOS activity in vitro in rat models of implantation. While AEA (0.70±0.02 vs 0.40±0.04) and URB-597 (1.08±0.09 vs 0.83±0.06) inhibited NOS activity in the absence of a blastocyst (pseudopregnancy) through CB2 receptors, AEA did not modulate NOS on day 5 pregnant uterus. Once implantation begins, URB-597 decreased NOS activity on day 6 implantation sites via CB1 receptors (0.25±0.04 vs 0.40±0.05). While a CB1 antagonist augmented NOS activity on day 6 inter-implantation sites (0.17±0.02 vs 0.27±0.02), a CB2 antagonist decreased it (0.17±0.02 vs 0.12±0.01). Finally, we described the expression and localization of cannabinoid receptors during implantation. In conclusion, AEA levels close to and at implantation sites seems to modulate NOS activity and thus nitric oxide production, fundamental for implantation, via cannabinoid receptors. This modulation depends on the presence of the blastocyst. These data establish cannabinoid receptors as an interesting target for the treatment of implantation deficiencies.
authors.affiliation: Laboratorio de Fisiología y Farmacología de la Reproducción, CEFYBO (CONICET-UBA), Buenos Aires, Argentina.
authors.forename: Micaela S
authors.initials: MS
authors.lastname: Sordelli
authors.forename: Jimena S
authors.initials: JS
authors.lastname: Beltrame
authors.forename: Juliana
authors.initials: J
authors.lastname: Burdet
authors.forename: Elsa
authors.initials: E
authors.lastname: Zotta
authors.forename: Romina
authors.initials: R
authors.lastname: Pardo
authors.forename: Maximiliano
authors.initials: M
authors.lastname: Cella
authors.forename: Ana M
authors.initials: AM
authors.lastname: Franchi
authors.forename: Maria Laura
authors.initials: ML
authors.lastname: Ribeiro
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology; D001755:Blastocyst / Q000166:cytology* / Q000502:physiology*; D063385:Cannabinoid Receptor Modulators / Q000494:pharmacology; D002219:Carbamates / Q000494:pharmacology; D010064:Embryo Implantation; D063388:Endocannabinoids; D005260:Female; D007150:Immunohistochemistry / Q000379:methods; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D053284:Polyunsaturated Alkamides / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000378:metabolism; D014599:Uterus / Q000187:drug effects* / Q000201:enzymology*
chemical_list: D001095:Arachidonic Acids; D001549:Benzamides; D063385:Cannabinoid Receptor Modulators; D002219:Carbamates; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C500528:cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester; D019001:Nitric Oxide Synthase; C078814:anandamide